Humacyte (NASDAQ:HUMA) Issues Quarterly Earnings Results

Humacyte (NASDAQ:HUMA) posted its quarterly earnings data on Wednesday. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.01, Zacks reports. Humacyte had a negative net margin of 1,998.87% and a negative return on equity of 990.48%.

Here are the key takeaways from Humacyte’s conference call:

• Symvess sales increased to $0.5 million in Q1 2026 from $0.1 million a year ago, but management said adoption is still too slow and that stronger commercial execution is needed.
• The company reshaped its commercial organization with new senior hires, including a Chief Commercial Officer and Chief Surgical Officer, to improve surgeon education, hospital penetration, and IDN coverage.
• Humacyte said its dialysis access Phase III trial is on track for top-line interim results around June 11, with 120 patients enrolled and a supplemental BLA planned for the second half of 2026 if results are positive.
• The company restructured its workforce in May, cutting 45 employees, and expects about $0.8 million in severance charges despite projecting roughly $14.3 million in savings for the rest of 2026.
• Humacyte ended Q1 with $48.9 million in cash and restricted cash; however, it reported a $17.6 million net loss, driven largely by lower non-cash income from contingent earn-out remeasurement.

Humacyte Stock Performance

Humacyte stock traded up $0.24 on Wednesday, reaching $1.15. 23,195,831 shares of the stock were exchanged, compared to its average volume of 6,454,625. The stock has a market cap of $255.10 million, a PE ratio of -5.69 and a beta of 2.31. The company has a current ratio of 3.69, a quick ratio of 2.95 and a debt-to-equity ratio of 20.08. Humacyte has a twelve month low of $0.55 and a twelve month high of $2.93. The firm has a fifty day moving average price of $0.86 and a two-hundred day moving average price of $1.07.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently bought and sold shares of the company. Atom Investors LP acquired a new position in shares of Humacyte during the fourth quarter valued at about $25,000. Financial Advisors Network Inc. acquired a new position in shares of Humacyte during the second quarter valued at about $28,000. Prudential Financial Inc. acquired a new position in shares of Humacyte during the second quarter valued at about $28,000. Equitable Holdings Inc. acquired a new position in shares of Humacyte during the third quarter valued at about $29,000. Finally, Imprint Wealth LLC acquired a new position in shares of Humacyte during the third quarter valued at about $33,000. Institutional investors and hedge funds own 44.71% of the company’s stock.

Analyst Ratings Changes

Several equities analysts have recently commented on the stock. Weiss Ratings restated a “sell (e+)” rating on shares of Humacyte in a report on Friday, April 10th. Wall Street Zen cut shares of Humacyte from a “sell” rating to a “strong sell” rating in a report on Saturday, April 11th. BTIG Research lowered their price target on shares of Humacyte from $3.00 to $2.00 and set a “buy” rating on the stock in a report on Wednesday. Benchmark decreased their price objective on shares of Humacyte from $11.00 to $10.00 and set a “buy” rating for the company in a report on Wednesday, January 21st. Finally, D. Boral Capital reiterated a “buy” rating and issued a $25.00 price objective on shares of Humacyte in a report on Tuesday, April 28th. Seven analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $7.57.

Humacyte Company Profile

Humacyte, Inc is a clinical-stage biotechnology company focused on the development and manufacturing of off-the-shelf, regenerative human acellular vessels (HAVs) designed to address critical vascular access needs. The company’s proprietary vessels are engineered from human donor cells and then decellularized to create a biocompatible scaffold capable of integrating with a patient’s own tissue. Humacyte’s primary business activities encompass process development, large-scale manufacturing, and clinical evaluation of HAVs for use in end-stage renal disease, peripheral arterial disease and other vascular repair applications.

The company’s lead product candidate, the HAV, has advanced through multiple clinical trials for arteriovenous access in hemodialysis patients, demonstrating durability, reduced infection rates and compatibility with repeated cannulation.